CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance

CONMED Corp

Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
GAAP EPS $0.45 vs $0.19 YoY; adjusted EPS $0.89 vs $0.95.
FY 2026 organic constant currency revenue growth guidance raised to 5.0-6.5% from 4.5-6.0%.
Reported revenue guidance raised to $1.350-1.375B; adjusted EPS reaffirmed $4.30-$4.45.
GI product exit impacted sales by $15.5M; company focusing on higher-growth areas.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.